Alkermes Plc Stock Today

ALKS Stock  USD 31.56  0.31  0.99%   

Performance

14 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Less than 1

 
High
 
Low
Very Small
Alkermes Plc is selling for under 31.56 as of the 29th of January 2025; that is 0.99 percent increase since the beginning of the trading day. The stock's lowest day price was 30.88. Alkermes Plc has a very small chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 1st of October 2024 and ending today, the 29th of January 2025. Click here to learn more.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. The company has 161.8 M outstanding shares of which 11.37 M shares are presently shorted by private and institutional investors with about 7.33 trading days to cover. More on Alkermes Plc

Moving against Alkermes Stock

  0.33MDGL Madrigal PharmaceuticalsPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Alkermes Stock Highlights

Chairman and CEORichard Pops
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, ARCA Pharmaceutical, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Financial Strength
Alkermes Plc (ALKS) is traded on NASDAQ Exchange in USA. It is located in Connaught House, Dublin, Ireland, D04 C5Y6 and employs 2,100 people. Alkermes Plc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.06 B. Alkermes Plc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 161.8 M outstanding shares of which 11.37 M shares are presently shorted by private and institutional investors with about 7.33 trading days to cover. Alkermes Plc currently holds about 580.97 M in cash with 401.35 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54.
Check Alkermes Plc Probability Of Bankruptcy
Ownership Allocation
The majority of Alkermes Plc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alkermes Plc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alkermes Plc. Please pay attention to any change in the institutional holdings of Alkermes Plc as this could imply that something significant has changed or is about to change at the company.
Check Alkermes Ownership Details

Alkermes Plc Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Alkermes Plc market risk premium is the additional return an investor will receive from holding Alkermes Plc long position in a well-diversified portfolio.

Alkermes Stock Against Markets

Alkermes Plc Corporate Management

Peter NormanSenior RelationsProfile
Iain BrownChief Accounting OfficerProfile
Blair JacksonExecutive OfficerProfile
Declan OConnorHealth EnvironmentProfile
Samuel ParisiInterim FinanceProfile

Already Invested in Alkermes Plc?

The danger of trading Alkermes Plc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alkermes Plc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alkermes Plc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alkermes Plc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Alkermes Stock Analysis

When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.